4579 Stock Overview
RaQualia Pharma Inc. engages in the research and development of pharmaceutical compounds worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
RaQualia Pharma Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥604.00 |
| 52 Week High | JP¥943.00 |
| 52 Week Low | JP¥587.00 |
| Beta | 0.61 |
| 1 Month Change | 0.17% |
| 3 Month Change | -7.93% |
| 1 Year Change | -24.31% |
| 3 Year Change | -39.84% |
| 5 Year Change | -62.11% |
| Change since IPO | -59.73% |
Recent News & Updates
Shareholder Returns
| 4579 | JP Pharmaceuticals | JP Market | |
|---|---|---|---|
| 7D | -1.0% | 2.7% | 1.8% |
| 1Y | -24.3% | 4.7% | 31.0% |
Price Volatility
| 4579 volatility | |
|---|---|
| 4579 Average Weekly Movement | 3.6% |
| Pharmaceuticals Industry Average Movement | 3.7% |
| Market Average Movement | 4.1% |
| 10% most volatile stocks in JP Market | 8.1% |
| 10% least volatile stocks in JP Market | 2.3% |
Stable Share Price: 4579 has not had significant price volatility in the past 3 months.
Volatility Over Time: 4579's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 67 | Hirobumi Takeuchi | www.raqualia.co.jp |
RaQualia Pharma Inc. engages in the research and development of pharmaceutical compounds worldwide. Its human products portfolio includes tegoprazan for gastroesophageal reflux disease, which is in phase 3 clinical trial in the United States; and grapiprant for cancer, which is in phase I clinical trial in China and the United States, as well as grapiprant for pain management The company also provides veterinary products, such as grapiprant for osteoarthritis in dogs; ghrelin receptor agonist to treat cancer-related anorexia/cachexia syndrome, and constipation resulting from spinal cord injury; and ELURA, a drug for the management of weight loss in cats with chronic kidney disease. In addition, it provides TRPM8 blocker for the indication of chronic pain; motilin receptor agonist to treat gastrointestinal dysmotility, including gastroparesis, functional dyspepsia, and post-operative ileus; 5-HT4 partial agonist to treat gastroparesis, functional dyspepsia, and chronic constipation; 5-HT2B antagonist to treat irritable bowel syndrome with diarrhea; EP4 antagonist, a pain management drugs for dogs; serotonin 5-HT2A and dopamine D2 receptor blocker to treat schizophrenia; EP4 antagonist to treat cancer that is in phase I clinical trial; Cyclooxygenase-2 inhibitor, which is in phase I clinical trials for the indication of pain; CB2 agonist for pain; selective sodium channel blocker for pain and itch; P2X7 receptor antagonist, which is in Phase 2 clinical trials for the target indication of chronic pain.
RaQualia Pharma Inc. Fundamentals Summary
| 4579 fundamental statistics | |
|---|---|
| Market cap | JP¥13.06b |
| Earnings (TTM) | -JP¥323.00m |
| Revenue (TTM) | JP¥1.90b |
6.9x
P/S Ratio-40.4x
P/E RatioIs 4579 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4579 income statement (TTM) | |
|---|---|
| Revenue | JP¥1.90b |
| Cost of Revenue | JP¥0 |
| Gross Profit | JP¥1.90b |
| Other Expenses | JP¥2.22b |
| Earnings | -JP¥323.00m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 15, 2024
| Earnings per share (EPS) | -14.94 |
| Gross Margin | 100.00% |
| Net Profit Margin | -16.99% |
| Debt/Equity Ratio | 0.8% |
How did 4579 perform over the long term?
See historical performance and comparison